MET blocks the proliferation of triple-negative breast cancer cells through the p21 cyclin-dependent inhibitory kinase pathway [147], and the peptide induces apoptosis in tumor cells and inhibits cervical carcinoma progression [159]. Here, MET is linked to neoplasm.